The association of outdoor temperature and self-reported Raynaud's phenomenon severity among people with systemic sclerosis: a Scleroderma Patient-centered Intervention Network Cohort study.

Autor:	Virgili-Gervais G; Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada., Matthews B; Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada., Nassar EL; Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada; Department of Psychiatry, McGill University, Montreal, QC, Canada., Carrier ME; Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada., Kwakkenbos L; Department of Clinical Psychology, Behavioural Science Institute, Radboud University, Nijmegen, Netherlands; Department of IQ Health, Radboud University Medical Center, Nijmegen, Netherlands; Centre for Mindfulness, Department of Psychiatry, Radboud University Medical Center, Nijmegen, Netherlands., Pauling JD; Department of Rheumatology, North Bristol NHS Trust, Bristol, UK; Musculoskeletal Research Unit, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK., Bartlett SJ; Department of Medicine, McGill University, Montreal, QC, Canada; Research Institute, McGill University Health Centre, Montreal, QC, Canada; Arthritis Research Canada, Vancouver, BC, Canada., Gietzen A; National Scleroderma Foundation, Tri-State Chapter, Buffalo, NY, USA., Gottesman K; National Scleroderma Foundation, Los Angeles, CA, USA., Guillot G; Sclérodermie Québec, Longueuil, QC, Canada., Hudson M; Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada; Department of Medicine, McGill University, Montreal, QC, Canada., Hummers LK; Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, USA., Lawrie-Jones A; Scleroderma Australia, Melbourne, VIC, Australia; Scleroderma Victoria, Melbourne, VIC, Australia., Malcarne VL; Department of Psychology, San Diego State University, San Diego, CA, USA; San Diego State University-University of California, San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA, USA., Mayes MD; University of Texas McGovern School of Medicine, Houston, TX, USA., Richard M; Scleroderma Atlantic, Halifax, NS, Canada., Sauvé M; Scleroderma Society of Ontario, Hamilton, ON, Canada; Scleroderma Canada, Hamilton, ON, Canada., Wojeck RK; University of Rhode Island, Kingston, RI, USA., Mouthon L; Service de Médecine Interne, Centre de Référence Maladies Autoimmunes et Autoinflammatoires Systémiques Rares d'Ile de France, de l'Est et de l'Ouest, Hôpital Cochin, Paris, France; Assistance Publique Hôpitaux de Paris-Centre, Université Paris Cité, Paris, France., Benedetti A; Department of Medicine, McGill University, Montreal, QC, Canada; Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC, Canada; Research Institute, McGill University Health Centre, Montreal, QC, Canada; Respiratory Epidemiology and Clinical Research Unit, McGill University Health Centre, Montreal, QC, Canada., Thombs BD; Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada; Department of Psychiatry, McGill University, Montreal, QC, Canada; Department of Medicine, McGill University, Montreal, QC, Canada; Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC, Canada; Biomedical Ethics Unit, McGill University, Montreal, QC, Canada; Department of Psychology, McGill University, Montreal, QC, Canada. Electronic address: brett.thombs@mcgill.ca.
Jazyk:	angličtina
Zdroj:	The Lancet. Rheumatology [Lancet Rheumatol] 2024 Oct; Vol. 6 (10), pp. e684-e692. Date of Electronic Publication: 2024 Aug 28.
DOI:	10.1016/S2665-9913(24)00189-9
Abstrakt:	Background: Raynaud's phenomenon is the earliest and most common systemic sclerosis manifestation. Episodes can be triggered by cold exposure and ambient temperature changes. Small studies have found that Raynaud's phenomenon outcomes were associated with season. We aimed to map the degree that differences in ambient temperature are associated with Raynaud's phenomenon outcomes across the temperature spectrum. Methods: People with Raynaud's phenomenon secondary to systemic sclerosis in the Scleroderma Patient-centered Intervention Network Cohort completed past-week Raynaud's phenomenon severity assessments (0-10 numerical rating scale) at enrolment and longitudinally at 3-month intervals. Mean daily temperature and feels like temperature, which incorporates wind chill and humidity, for the week before each assessment were extracted for each participant from a weather site close to the participant's recruiting centre via the Iowa Environmental Mesonet. We used linear mixed models with basis splines to flexibly model non-linear changes in Raynaud's phenomenon severity across the temperature spectrum. People with lived experience of systemic sclerosis contributed to the study design and interpretation. Findings: Between April 15, 2014 and Aug 1, 2023, we included data on 20 233 Raynaud's phenomenon severity assessments from 2243 participants. 1964 (88%) of 2243 participants were women, 279 (12%) were men, and 1813 (82%) were White. Mean age was 54·8 (SD 12·7) years. The maximum predicted Raynaud's phenomenon severity score was 6·8 points (95% CI 5·6-8·1), which occurred at -25°C. Severity scores decreased minimally from -15°C to 5°C (0·05-0·21 points per 5°C difference), then decreased in larger steps between 5°C and 25°C (0·37-0·54 points per 5°C difference). The minimum predicted score was at 25°C (2·6 points [95% CI 2·5-2·7]). Scores increased at temperatures above 25°C to 3·5 points (3·0-4·1) at 35°C and 5·6 points (4·5-6·8) at 40°C. Results were similar for feels like temperature. Interpretation: Raynaud's phenomenon severity is worst at very cold temperatures but also increases with very warm temperatures, presumably due to air conditioning. Clinical management and Raynaud's phenomenon intervention trial designs should consider temperature patterns. Funding: Scleroderma Society of Ontario, Scleroderma Canada, Sclérodermie Québec, Scleroderma Manitoba, Scleroderma Atlantic, Scleroderma Association of BC, Scleroderma SASK, Scleroderma Australia, Scleroderma New South Wales, Scleroderma Victoria, the Canadian Institutes of Health Research, the Arthritis Society, the Lady Davis Institute for Medical Research of the Jewish General Hospital, the Jewish General Hospital Foundation, and McGill University. Competing Interests: Declaration of interests JDP has received speaker honoraria or consultancy fees from Astra Zeneca, Boehringer Ingelheim, IsoMab, Janssen, Permeatus, and Sojournix Pharma. MDM has received research grants or contracts from Prometheus Biosciences, Mitsubishi Tanabe, Boehringer Ingelheim, EICOS, Corbus, and Horizon Pharma; consulting fees from Cabaletta Pharma; an honorarium from GSK Pharma; and was a member of a data safety monitoring board or advisory board with Mitsubishi Tanabe, Boehringer Ingelheim, and EICOS. All other authors declare no competing interests. (Copyright © 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu